Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘TAK-700’

Update on Orteronel TAK-700 from EAU 2012 Paris #EAU12

By on February 26, 2012

There are no major presentations of phase III clinical trial data at the European Association of Urology (EAU) Congress in Paris this weekend, but interesting clinical and scientific data is still being presented.

If you want to understand the competitive dynamics of the prostate cancer market and the market opportunity with urologists, then you need to be at meetings such as EAU in Europe and AUA in the United States.

EAU 2012 Prostate Cancer Poster Session1 225x300 Update on Orteronel TAK 700 from EAU 2012 Paris #EAU12There was a lot of interest in yesterday’s advanced prostate cancer poster session at EAU 2012.

This is a preview of Update on Orteronel TAK-700 from EAU 2012 Paris #EAU12. Read the full post

Leave a comment

MDV3100 shows survival in Advanced Prostate Cancer

By on November 3, 2011

Medivation Logo MDV3100 shows survival in Advanced Prostate Cancer Prostate cancer is the second leading cause of cancer death in men, so it was good news this morning when Medivation & Astellas issued a press release that showed positive data from the phase 3 AFFIRM trial for MDV3100.

MDV3100 produced a 4.8-month advantage in median overall survival compared to placebo.

The estimated median survival for men treated with MDV3100 was 18.4 months compared with 13.6 months for men treated with placebo.

MDV3100 provided a 37 percent reduction in risk of death compared to placebo (Hazard Ratio=0.631).

This is a preview of MDV3100 shows survival in Advanced Prostate Cancer. Read the full post

Leave a comment

Alpharadin on fast track to FDA prostate cancer approval in 2012

By on August 25, 2011

Algeta Alpharadin 223 147x300 Alpharadin on fast track to FDA prostate cancer approval in 2012

Earlier this week Bayer & Algeta announced that Alpharadin™ (radium-223 chloride) had received Fast Track designation from the FDA for the treatment of castration-resistant prostate cancer (CRPC).

Bayer signed an agreement with Norwegian based Algeta in 2009 for the global commercial rights to Alpharadin™, with Algeta retaining a 50/50 co-promotion and profit-sharing in the United States.

According to the Algeta August 23, 2011 press release, in light of the FDA fast track designation they plan on filing for United States approval in mid-2012, ahead of previous expectations.

This is a preview of Alpharadin on fast track to FDA prostate cancer approval in 2012. Read the full post

Leave a comment

Update from AACR on new prostate cancer drugs to watch

By on April 7, 2011

AACR 2011 Annual Meeting Banner 300x225 Update from AACR on new prostate cancer drugs to watchThe 102nd Annual meeting of the American Association for Cancer Research (AACR) ended yesterday in Orlando, and it was only the diehards who kept going till the last session of the last day for an update on “Novel Androgen Receptor Antagonists.”

As I mentioned in an earlier post, there is a lot of excitement in the prostate cancer field at the moment with three new therapies approved last year (cabazitaxel, sipuleucel-T, denosumab), and more expected over the next two years (abiraterone acetate, MDV3100, cabozantinib/XL-184).

This is a preview of Update from AACR on new prostate cancer drugs to watch. Read the full post

Leave a comment